Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 3
2006 3
2007 1
2008 1
2009 2
2010 2
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.
Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Möttönen T; FIN-RACo Trial Group. Rantalaiho VM, et al. Ann Rheum Dis. 2013 May;72(5):786-8. doi: 10.1136/annrheumdis-2012-202737. Epub 2013 Jan 24. Ann Rheum Dis. 2013. PMID: 23349132 Clinical Trial. No abstract available.
Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.
Puolakka K, Kautiainen H, Pekurinen M, Möttönen T, Hannonen P, Korpela M, Hakala M, Arkela-Kautiainen M, Luukkainen R, Leirisalo-Repo M; FIN-RACo Trial Group. Puolakka K, et al. Ann Rheum Dis. 2006 Jul;65(7):899-904. doi: 10.1136/ard.2005.045807. Epub 2005 Nov 16. Ann Rheum Dis. 2006. PMID: 16291811 Free PMC article.
Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M; FIN-RACo Trial Group. Puolakka K, et al. Arthritis Rheum. 2005 Jan;52(1):36-41. doi: 10.1002/art.20716. Arthritis Rheum. 2005. PMID: 15641055 Free article. Clinical Trial.
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group. Rantalaiho V, et al. Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24. Arthritis Res Ther. 2010. PMID: 20576092 Free PMC article. Clinical Trial.
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study.
Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T; FIN-RACo Trial Group. Korpela M, et al. Arthritis Rheum. 2004 Jul;50(7):2072-81. doi: 10.1002/art.20351. Arthritis Rheum. 2004. PMID: 15248204 Free article. Clinical Trial.
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J; FIN-RACo Trial Group. Laivoranta-Nyman S, et al. Clin Exp Rheumatol. 2006 Nov-Dec;24(6):636-42. Clin Exp Rheumatol. 2006. PMID: 17207378 Clinical Trial.
The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group. Rantalaiho V, et al. Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447. Arthritis Rheum. 2009. PMID: 19404945 Free article. Clinical Trial.
HLA-DR-DQ haplotypes and genotypes in Finnish patients with rheumatoid arthritis.
Laivoranta-Nyman S, Möttönen T, Hermann R, Tuokko J, Luukkainen R, Hakala M, Hannonen P, Korpela M, Yli-Kerttula U, Toivanen A, Ilonen J; FIN-RACo Trial Group. Laivoranta-Nyman S, et al. Ann Rheum Dis. 2004 Nov;63(11):1406-12. doi: 10.1136/ard.2003.009969. Ann Rheum Dis. 2004. PMID: 15479890 Free PMC article.
15 results